SHOP APOTHEKE EUROPE N.V.

  • WKN: A2AR94
  • ISIN: NL0012044747
  • Land: Niederlande

Nachricht vom 13.03.2018 | 15:41

SHOP APOTHEKE EUROPE N.V. PUBLISHES AGM CONVOCATION AND AGENDA.

DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): AGM/EGM

13.03.2018 / 15:41
The issuer is solely responsible for the content of this announcement.


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN.

SHOP APOTHEKE EUROPE N.V. PUBLISHES AGM CONVOCATION AND AGENDA.

Venlo, Cologne, 13 March 2018. SHOP APOTHEKE EUROPE N.V. ("SHOP APOTHEKE EUROPE" or the "Company") has today published the convocation for the annual general meeting of shareholders of the Company (the "AGM"), including the agenda, the accompanying explanatory notes and other information/documentation on its website 

http://shop-apotheke-europe.com/en/investorrelations/hauptversammlung/

The AGM will take place on 26 April 2018 at 10:00 CEST at Van der Valk Hotel Venlo, Nijmeegseweg 90, 5916 PT Venlo, The Netherlands.


For further information please contact us at:

Investor Relations:
Dr. Ulrich Wandel                             
Telephone: +31 77 850 6117                                                
Email: ulrich.wandel@shop-apotheke.com

Trade and public media:
Sven Schirmer                                               
Mobile: +49 152 28 50 63 61                                                
Email: presse@shop-apotheke.com
 
Financial media:
Thomas Schnorrenberg                               
Mobile: +49 151 46 53 13 17                                    
Email: presse@shop-apotheke.com
 


ABOUT SHOP APOTHEKE EUROPE.
 
SHOP APOTHEKE EUROPE is the leading and fastest growing online pharmacy in Continental Europe. With the acquisition of Europa Apotheek Venlo in November 2017, SHOP APOTHEKE EUROPE significantly extended its European market leadership with an expanded product range for the whole family in the areas of OTC, beauty and care products as well as prescription drugs
 
SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, the TÜV-certified shop-apotheke.com is the market leader in terms of traffic. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to about 2.7 million active customers quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.
 
SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.

 

DISCLAIMER.
 
This announcement does not constitute a public offer or an offer to subscribe to any securities in any jurisdiction.
 
This announcement may contain forward-looking statements that relate to the future course of business and future financial performance, as well as future transactions or developments concerning SHOP APOTHEKE EUROPE. The bases of these statements are current expectations and assumptions of SHOP APOTHEKE EUROPE's management, of which a large number are outside SHOPE APOTHEKE EUROPE's sphere of influence. These statements are therefore subject to a variety of risks and uncertainties. If such risks and uncertainties occur, or if the underlying expectations do not materialize or the assumptions made are not correct, the actual events, both positive and negative, may differ materially from those events contained in the forward-looking statements. SHOP APOTHEKE EUROPE assumes no obligation to update these forward-looking statements or to correct them in the event of occurrences or developments other than those anticipated. Such updates or corrections are not intended.
 


 


13.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Hohes Kurspotenzial: „Attraktiver „Value-add“-Immobilienspezialist

Die Coreo AG führt derzeit eine Bezugsrechtskapitalerhöhung durch, in deren Rahmen ein Bruttoemissionserlös von bis zu 16 Mio. € angestrebt wird. Der Liquiditätserlös soll zum Erwerb von Gewerbe- und Wohnimmobilien für den Geschäftsbereich „Value Add“ verwendet werden. Derzeit, also pre money, verfügt die Gesellschaft über ein prognostiziertes NAV (auf Grundlage von GBC-Berechnungen) von 2,40 €. Für das laufende und kommende Geschäftsjahr rechnen wir mit einem spürbaren Ertrags- und Ergebnisanstieg. Neben der Steigerung von Mieterträgen sollte die Gesellschaft im nennenswerten Umfang Veräußerungserlöse erzielen sowie stille Reserven aufdecken. Auf Basis unseres DCF-Bewertungsmodells (post money) haben wir ein Kursziel von 3,10 € ermittelt. Auf Basis des aktuellen Kurses sowie des Platzierungspreises im Rahmen der Kapitalerhöhung von 1,60 € je Aktie lautet unserer Einschätzung KAUFEN.“

Aktuelle Research-Studie

Original-Research: UniDevice AG (von GBC AG): Vorstandsinterview UniDevice AG

18. Dezember 2018